Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Elena Christofides

Endocrinology, Diabetes & Metabolism Columbus, OH Medical Doctor

NPI 1306893433 CMS profile 58640

72 W 3Rd Ave, Columbus, OH 43201

Open in the dashboard

General payments

$2,303,560

3,409 records reported · program years 2019–2025

Research payments

$109,968

Paid to them · 36 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,225,492 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Elena Christofides of Columbus, OH is reported in the CMS Open Payments database as having received $2,303,560 across 3,409 general payments and $109,968 in research payments paid to them. Separately, studies naming them as principal investigator received $1,225,492 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $424,213 568
2025 Research $3,982 16
2024 General $298,800 433
2024 Research $67,466 2
2023 General $224,814 375
2023 Research $11,582 9
2022 General $353,383 507
2022 Research $26,027 2
2021 General $307,771 417
2021 Research $911 7
2020 General $291,384 408
2019 General $403,194 701

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elena Christofides
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Elena Christofides were reported at $424,213. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Elena Christofides Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $403,194 $494 $123–$2,253 $163
2020 $291,384 $335 $85–$1,841 $114
2021 $307,771 $398 $88–$1,981 $132
2022 $353,383 $364 $88–$1,568 $149
2023 $224,814 $420 $113–$1,614 $160
2024 $298,800 $440 $121–$1,646 $164
2025 $424,213 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $589,906 749 payments
  2. Corcept Therapeutics $327,601 396 payments
  3. Novo Nordisk Inc $223,037 403 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $202,478 247 payments
  5. Xeris Pharmaceuticals, Inc. $156,527 203 payments
  6. Recordati_Rare_Diseases_Inc. $155,447 176 payments
  7. AbbVie, Inc. $134,642 228 payments
  8. Ascendis Pharma, Inc. $124,148 170 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $114,056 148 payments
  10. Amryt Pharma Holdings Ltd $66,144 81 payments
  11. Other $209,574 608 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,557,171 869 payments
  2. Honoraria $287,790 98 payments
  3. Travel and Lodging $241,215 854 payments
  4. Consulting Fee $161,516 76 payments
  5. Food and Beverage $53,029 1,503 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $1,500 1 payment
  7. Education $1,338 8 payments
Products named General payments · program years 2019–2025
  1. Korlym $327,274 391 payments
  2. TRULICITY $260,987 314 payments
  3. Kerendia $196,634 237 payments
  4. JARDIANCE Diabetes $175,170 196 payments
  5. ISTURISA $149,249 173 payments
  6. RECORLEV $141,824 179 payments
  7. MOUNJARO $137,634 201 payments
  8. Ozempic $117,139 245 payments
  9. JARDIANCE Diabetes $93,412 114 payments
  10. Yorvipath $80,254 117 payments
  11. Other $457,935 1,274 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $102,931 4 payments
  2. Corcept Therapeutics $4,298 23 payments
  3. Recordati_Rare_Diseases_Inc. $2,739 9 payments

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

1,380

Median for Endocrinology: 1,959

Drug cost

$1,784,275

Median for Endocrinology: $890,201

Branded share of claims

61.6%

Median for Endocrinology: 57%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Recorlev Levoketoconazole Brand 33 $606,500
Isturisa Osilodrostat Phosphate Brand 39 $567,470
Genotropin Somatropin Brand 33 $121,436
Ozempic Semaglutide Brand 88 $107,074
Mounjaro Tirzepatide Brand 79 $105,023
Jardiance Empagliflozin Brand 66 $67,897
Omnitrope Somatropin Brand 26 $58,951
Trulicity Dulaglutide Brand 31 $32,287
Kerendia Finerenone Brand 32 $27,692
Prolia Denosumab Brand 11 $19,145

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$31,569

Medicare's payments for the services billed

Medicare patients

101

Average age 71

Services billed

333

67 women, 34 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 61%
Arthritis 47%
Chronic kidney disease 33%
Ischemic heart disease 28%
Depression 25%
Osteoporosis 23%
Heart failure 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Korlym
$91,113 — —
ISTURISA
$56,293 39 —
MOUNJARO
$44,762 79 —
JARDIANCE
$33,765 66 —
RECORLEV
$30,328 33 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

3,445 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record